Skip to main content

Table 3 Hospital resource use up to 6 months for trial participants

From: Cost-effectiveness of a cardiac output-guided haemodynamic therapy algorithm in high-risk patients undergoing major gastrointestinal surgery

 

Peri-operative cardiac output-guided, haemodynamic therapy algorithm

Usual care

(n = 368)

(n = 365)

Surgery

  

 Upper gastrointestinal

108 (29.4)

111 (30.4)

 Lower gastrointestinal

168 (45.7)

165 (45.2)

 Small bowel +/− pancreas

86 (23.4)

82 (22.5)

 Urological or gynaecological involving gut

5 (1.4)

4 (1.1)

 No surgery performed

1 (0.3)

3 (0.8)

Intervention

  

 Cardiac monitor used

364 (98.9)

31 (8.5)

 Dopexamine dose infused (mg)

18.9 (8.4)

–

 Intra-venous crystalloid (ml)

  

  During surgery

1518 (1410)

2420 (1382)

  6 h following surgery

565 (254)

670 (367)

 Intra-venous colloid (ml)

  

  During surgery

1465 (913)

708 (695)

  6 h following surgery

642 (498)

226 (361)

 Blood products (ml)

  

  During surgery

141 (723)

95 (542)

  6 h following surgery

80 (555)

10 (66)

Length of stay (days)

  

 Critical care level 2

2.5 (3.7)

2.6 (3.4)

 Critical care level 3

0.7 (2.4)

0.9 (3.8)

 General surgical ward

10.3 (14.4)

11.4 (12.6)

  1. Data presented as mean (SD) or n (%)